Ⅰ期肺腺癌新分類組織亞型與EGFR突變的關(guān)系
發(fā)布時(shí)間:2018-04-03 18:11
本文選題:肺腫瘤 切入點(diǎn):腺癌 出處:《腫瘤》2017年01期
【摘要】:目的 :按照2011年國(guó)際肺癌研究學(xué)會(huì)(International Association for the Study of Lung Cancer,IASLC)/美國(guó)胸科學(xué)會(huì)(American Thoracic Society,ATS)和歐洲呼吸學(xué)會(huì)(European Respiratory Society,ERS)制定的國(guó)際多學(xué)科肺腺癌分類標(biāo)準(zhǔn),探討Ⅰ期肺腺癌的組織亞型與表皮生長(zhǎng)因子受體(epidermal growth factor receptor,EGFR)突變間的關(guān)系。方法 :應(yīng)用二代測(cè)序技術(shù)檢測(cè)100例明確組織亞型的Ⅰ期肺腺癌組織標(biāo)本EGFR的突變情況,分析肺腺癌不同組織亞型和肺腺癌患者的臨床病理特征與EGFR突變間的關(guān)系。結(jié)果 :100例肺腺癌患者中,49例(49.0%)發(fā)生EGFR突變。其中,貼壁為主亞型EGFR突變23例(63.9%),乳頭為主亞型突變5例(62.5%),腺泡為主亞型突變21例(46.7%),微乳頭為主亞型和固態(tài)或黏液為主亞型均無突變。Ⅰ期肺腺癌EGFR突變與組織亞型相關(guān)(P=0.002)。存在貼壁組織成分的腺癌中EGFR突變率(60.8%)明顯高于缺乏貼壁組織成分的腺癌(36.7%,P=0.018),存在固態(tài)/黏液組織成分的腺癌中EGFR突變率(20.0%)明顯低于缺乏固態(tài)/黏液組織成分的腺癌(54.1%,P=0.015)。EGFR突變與肺腺癌的分化程度有關(guān)(P=0.001),而與性別、年齡、吸煙、腫瘤大小和胸膜轉(zhuǎn)移均無關(guān)(P值均0.05)。結(jié)論 :Ⅰ期肺腺癌中貼壁為主亞型或存在貼壁組織成分的腺癌具有較高的EGFR突變率,EGFR突變與肺腺癌的分化程度有關(guān)。
[Abstract]:Objective: according to the International Association for the Study of Lung Cancer IASLCN / American Thoracic Society ATS (2011) and the European Respiratory Society (ERS) of the European Society of Respiratory Sciences, the international classification criteria for lung adenocarcinoma were established in accordance with the International Association for the Study of Lung Cancer IASC / American Thoracic Society ATS (2011) and the European Respiratory Society (ERS) of the European Society of Respiratory Sciences (ESR).To investigate the relationship between histological subtypes of stage I lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutation in epidermal growth factor receptor (EGFR).Methods: second generation sequencing technique was used to detect the mutation of EGFR in 100 cases of stage I lung adenocarcinoma with definite tissue subtypes. The relationship between EGFR mutation and clinicopathological features of different subtypes of lung adenocarcinoma and lung adenocarcinoma was analyzed.Results EGFR mutation occurred in 49 out of 100 lung adenocarcinoma patients.鍏朵腑,璐村涓轟富浜氬瀷EGFR紿佸彉23渚,
本文編號(hào):1706334
本文鏈接:http://sikaile.net/yixuelunwen/zlx/1706334.html
最近更新
教材專著